1. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007;68 8:609-11; doi: 68/8/609 [pii] 10.1212/01.wnl.0000254620.45529.97.
2. Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007;261 1-2:127-33; doi: S0022-510X(07)00312-7 [pii] 10.1016/j.jns.2007.04.045.
3. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48 5:1253-60.
4. Keesey JC. "Crisis" in myasthenia gravis: an historical perspective. Muscle Nerve. 2002;26 1:1-3; doi: 10.1002/mus.10095.
5. Chaudhuri A, Behan PO. Myasthenic crisis. QJM. 2009;102 2:97-107; doi: 10.1093/qjmed/hcn152.
6. Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci. 1981;377:670-7.
7. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72 18:1548-54; doi: 10.1212/WNL.0b013e3181a41211.
8. Ferguson IT, Murphy RP, Lascelles RG. Ventilatory failure in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1982;45 3:217-22.
9. Sharma S, Lal V, Prabhakar S, Agarwal R. Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study. Ann Indian Acad Neurol. 2013;16 2:203-7; doi: 10.4103/0972-2327.112466.
10. Spillane J, Hirsch NP, Kullmann DM, Taylor C, Howard RS. Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis. Eur J Neurol. 2014;21 1:171-3; doi: 10.1111/ene.12115.
11. Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. South Med J. 2008;101 1:63-9; doi: 10.1097/SMJ.0b013e31815d4398 00007611-200801000-00024 [pii].
12. Wang W, Chen YP, Wang ZK, Wei DN, Yin L. A cohort study on myasthenia gravis patients in China. Neurol Sci. 2013;34 10:1759-64; doi: 10.1007/s10072-013-1329-5.
13. Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci. 2003;998:413-23.
14. Sakaguchi H, Yamashita S, Hirano T, Nakajima M, Kimura E, Maeda Y, et al. Myasthenic crisis patients who require intensive care unit management. Muscle Nerve. 2012;46 3:440-2; doi: 10.1002/mus.23445.
15. Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006;13 10:1006-10; doi: 10.1016/j.jocn.2005.12.041.
16. Tomiyama M, Arai A, Kimura T, Suzuki C, Watanabe M, Kawarabayashi T, et al. Exacerbation of chronic pancreatitis induced by anticholinesterase medications in myasthenia gravis. Eur J Neurol. 2008;15 5:e40-1; doi: 10.1111/j.1468-1331.2008.02098.x.
17. Godoy DA, Mello LJ, Masotti L, Di Napoli M. The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit. Arq Neuropsiquiatr. 2013;71 9A:627-39; doi: 10.1590/0004-282X20130108.
18. Lacomis D. Myasthenic crisis. Neurocrit Care. 2005;3 3:189-94; doi: 10.1385/NCC:3:3:189.
19. Plauche WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol. 1991;34 1:82-99.
20. Gracey DR, Divertie MB, Howard FM, Jr. Mechanical ventilation for respiratory failure in myasthenia gravis. Two-year experience with 22 patients. Mayo Clin Proc. 1983;58 9:597-602.
21. Kiphuth IC, Schellinger PD, Kohrmann M, Bardutzky J, Lucking H, Kloska S, et al. Predictors for good functional outcome after neurocritical care. Crit Care. 2010;14 4:R136; doi: cc9192 [pii] 10.1186/cc9192.
22. Cabrera Serrano M, Rabinstein AA. Usefulness of pulmonary function tests and blood gases in acute neuromuscular respiratory failure. Eur J Neurol. 2012;19 3:452-6; doi: 10.1111/j.1468-1331.2011.03539.x.
23. Werneck LC, Scola RH, Germiniani FM, Comerlato EA, Cunha FM. Myasthenic crisis: report of 24 cases. Arq Neuropsiquiatr. 2002;60 3-A:519-26; doi: S0004-282X2002000400001 [pii].
24. Panda S, Goyal V, Behari M, Singh S, Srivastava T. Myasthenic crisis: a retrospective study. Neurol India. 2004;52 4:453-6.
25. Murthy JM, Meena AK, Chowdary GV, Naryanan JT. Myasthenic crisis: clinical features, complications and mortality. Neurol India. 2005;53 1:37-40; discussion
26. Lee CY, Lam CL, Pang SY, Lau KK, Teo KC, Chang RS, et al. Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese. J Neuroimmunol. 2015;289:177-81; doi: 10.1016/j.jneuroim.2015.10.018.
27. Liu C, Wang Q, Qiu Z, Lin J, Chen B, Li Y, et al. Analysis of mortality and related factors in 2195 adult myasthenia gravis patients in a 10-year follow-up study. Neurol India. 2017;65 3:518-24; doi: 10.4103/neuroindia.NI_804_16.
28. Fraisse T, Labauge P, Camu W, Arlaud P, de Wazieres B. [Myasthenia gravis in the elderly: diagnosis, comorbidity and course: 45 cases]. Presse Med. 2007;36 1 Pt 1:9-14; doi: 10.1016/j.lpm.2006.07.003.